AbbVie Inc. (BVMF:ABBV34)

Brazil flag Brazil · Delayed Price · Currency is BRL
76.89
+1.44 (1.91%)
At close: Dec 5, 2025
16.11%
Market Cap 2.16T
Revenue (ttm) 317.87B
Net Income (ttm) 12.51B
Shares Out n/a
EPS (ttm) 7.04
PE Ratio 172.83
Forward PE 16.52
Dividend 1.54 (2.04%)
Ex-Dividend Date Oct 14, 2025
Volume 71
Average Volume 3,075
Open 75.45
Previous Close 75.45
Day's Range 75.24 - 76.98
52-Week Range 60.00 - 81.36
Beta 0.35
RSI 52.36
Earnings Date Jan 30, 2026

About AbbVie

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancer... [Read more]

Sector Healthcare
Founded 2012
Employees 55,000
Stock Exchange Brazil Stock Exchange
Ticker Symbol ABBV34
Full Company Profile

Financial Performance

In 2024, AbbVie's revenue was $56.33 billion, an increase of 3.71% compared to the previous year's $54.32 billion. Earnings were $4.24 billion, a decrease of -12.07%.

Financial numbers in USD Financial Statements

News

There is no news available yet.